Amilorides inhibit SARS-CoV-2 replication in vitro by targeting RNA structures

Abstract

Department

Description

Provenance

Subjects

Citation

Published Version (Please cite this version)

10.1126/sciadv.abl6096

Publication Info

Zafferani, Martina, Christina Haddad, Le Luo, Jesse Davila-Calderon, Liang-Yuan Chiu, Christian Shema Mugisha, Adeline G Monaghan, Andrew A Kennedy, et al. (2021). Amilorides inhibit SARS-CoV-2 replication in vitro by targeting RNA structures. Science Advances, 7(48). 10.1126/sciadv.abl6096 Retrieved from https://hdl.handle.net/10161/24025.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.

Scholars@Duke

Hargrove

Amanda Hargrove

Professor of Chemistry

The Hargrove lab harnesses the unique properties of small organic molecules to study the structure, function and therapeutic potential of long noncoding RNAs (lncRNAs). The discovery of these fascinating biomolecules has caused a paradigm shift in molecular biology and speculation as to their role as the master drivers of diseases such as cancer. At the same time very little is known about their structure and function, leading some to call the field a veritable “wild West.” Small molecules are the perfect tools for such exploration, and the Hargrove lab works at the interface of chemistry and biology, employing methods ranging from RNA-targeted small molecule synthesis and array-based pattern recognition to studies of the molecular and cellular biology of nucleic acids. Collaborations with the Department of Biology as well as colleagues in the School of Medicine ensure that these tools are applied to the most important unsolved problems in the fundamental biology and disease-related actions of long noncoding RNAs.


Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.